Clinical Trial

A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase I/II trial of T-cell expressing an anti-CD22 Chimeric-Antigen-Receptor (CAR) in patients with CD22 expressing B-cell malignancies. This trial is an open label, single-arm, for pediatric and adult patients with relapsed/refractory B-cell malignancies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-13.
Status change: Not Yet Recruiting → Recruiting 2026-01-14
Trial Details
NCT Number NCT07135466
Lead Sponsor Sheba Medical Center
Conditions B Cell Malignancies
Enrollment 50 participants
Start Date 2026-02-01
Primary Completion 2027-04-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-16